BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Contract Services

WuXi AppTec Raises 2026 Interim Dividend to RMB 1.51 Billion Amid Global CRDMO Expansion

WuXi AppTec Co., Ltd. (Stock Codes: 603259.SH/2359.HK), a leading global pharmaceutical CRDMO (Contract Research, Development, and Manufacturing Organizati...

September 01, 2026 | News

Samsung Biologics to Raise KRW 3 Trillion to Fund PolyPeptide Acquisition and Manufacturing Expansion

Samsung Biologics announced a rights offering to raise an expected aggregate amount of KRW 3 trillion to fund investments in the company's three-dimensiona...

August 31, 2026 | News

HiRO and Differentia Join Forces to Advance AI-Powered Clinical Trial Simulation and Digital Twins

Memorandum of Understanding establishes a framework for joint development of clinical trial simulation capabilities The partnership unites global clinic...

August 31, 2026 | News

Piramal Pharma Acquires Majority Stake in Yapan Bio to Strengthen Biologics CDMO Capabilities

Yapan Bio Private Limited specializes in process development, characterization, and phase I and II GMP manufacturing services for vaccines and biologics....

August 20, 2026 | News

Merck Expands Singapore BioReliance Lab with First Cell Line Characterisation and GMP NGS Capabilities in Asia Pacific

Expansion adds first BioReliance® Cell Line Characterization and GMP Next-Generation Sequencing in Asia Pacific Enhanced testing capabilities t...

August 12, 2026 | News

Porton Advanced Secures China Commercial Manufacturing Licence for Cell and Gene Therapy CDMO Services

Porton Advanced Solutions Ltd. ("Porton Advanced") has officially been granted a Drug Manufacturing License (Class C) by the National Medical Products Admi...

August 07, 2026 | News

Enzene Launches NeX™ to Enable Local Biologics Manufacturing Worldwide

Enzene, a leading global continuously innovative development and manufacturing organization (CIDMO™), announced the launch of NeX™, a transform...

August 05, 2026 | News

The APAC CDMO Shortlist: 10 CDMOs to Watch Through 2028

There is a version of this list that writes itself. Rank the region’s contract manufacturers by installed litres, put Samsung Biologics at the top, a...

July 24, 2026 | Analysis

Samsung Bioepis Secures Exclusive Commercial Rights to Nectin-4 ADC Candidate SBE303

Ÿ Under the agreement, Samsung Bioepis will obtain exclusive commercial licensing rights to SBE303, an ADC candidate currently in joi...

July 24, 2026 | News

Lonza and Engitix Partner to Advance Next-Generation ECM-Targeted ADCs

Lonza grants Engitix target-specific license for GlycoConnect®, HydraSpace® and SYNtecan E™ linker-payload technologies for ADC de...

July 22, 2026 | News

Samsung Biologics Launches CHF 1.46B All-Cash Bid to Acquire PolyPeptide

Samsung Biologics to launch an all-cash public tender offer for 100% of PolyPeptide's fully diluted share capital (excluding therefrom any treasury share...

July 21, 2026 | News

Merck Invests €25M to Expand BioReliance Testing Capabilities in Europe

• New 2,000-square-meter facility expands Merck’s global testing network with commercial drug substance and drug product release testing a...

July 17, 2026 | News

China Plus One: Slogan, Strategy, or Capacity APAC Does Not Have?

THE RESHUFFLE · ANALYSIS On a Monday in June 2026, one line in the United States Federal Register did what two year...

July 16, 2026 | Analysis

Can APAC Biomanufacturing Decarbonise Without Pricing Itself Out?

Scope 3 clauses, single-use plastic, water and energy intensity: the “green premium” has become the defining question for the CDMOs that built ...

July 14, 2026 | Analysis

Stay Connected